Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5

Antibody Therapeutics(2023)10.1093/abt/tbad006Source: DataRank Database

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5 is a research paper published in Antibody Therapeutics (2023). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: goldTopics (8)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Jonathan K. Fleming,Paul D. Entzminger,Lisa Yuko Espinosa,Alex Samadi,Yuko Hiramoto

Live enrichment

PubMed:37324547 PMC:PMC10262839

National Institutes of Health

Grant: U19 AI142790-S1

Bill and Melinda Gates Foundation

Grant: OPP1210938

COVID-19 Therapeutics Accelerator

Grant: INV-006133

National Institutes of Health

Grant: 5U19AI142790-04

Consortium for Immunotherapeutics against Emerging Viral Threats

Abwiz Bio Inc

GHR Foundation

goldLicense: cc-by

publisherhttps://academic.oup.com/abt/advance-article-pdf/doi/10.1093/abt/tbad006/49879814/tbad006.pdf

publisherhttps://academic.oup.com/abt/advance-article-pdf/doi/10.1093/abt/tbad006/50311010/tbad006.pdf

publisherhttps://academic.oup.com/abt/article-pdf/6/2/108/50569251/tbad006.pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10262839/pdf/tbad006.pdf

Europe_PMChttps://europepmc.org/articles/PMC10262839

Fields of Study

0303 health sciences03 medical and health sciences

Keywords

Antibody engineeringNeutralizing antibodyCovid-19Sars-cov-2Xbb.1.5Research Article

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5

FAIR Checklist

Authors (8)

Funding (6 grants)

Open Access

Topics

Annotations (Europe PMC)